SlideShare ist ein Scribd-Unternehmen logo
1 von 17
PHARMACEUTICAL SECTOR OF SERBIA


  Vekoslav Šošević, Secretary of Association of Chemical and
   Pharmaceutical Industry, Rubber and Non-Metal Industry



                    25 th October 2012, Rome
PHARMACEUTICAL INDUSTRY - ECONOMIC OVERVIEW

   Share of pharmaceutical sector in GDP - 0,7%
   Gross production of the industry - over 450 mil. Euro (2011)
   Total consumption of medicines in Serbia - 740 mil. Euro
   Annual production rate ~10%
   Number of employees - 7000
   Export oriented (155 mil Euro of goods were exported in 2011)
   Direct contribution to the budget of the Republic of Serbia (2011) ~40 mil. Euro (taxes,
    contribution, customs)
TRADE FLOW OF DOMESTIC PRODUCERS FROM SERBIA IN 2011

 For years, domestic pharmaceutical industry has been a carrier of stable supply of the market with
  medicines of all forms and dosages
 Total consumption of medicines in Serbia for 2011 is estimated to around 740 mil. Euros. Share of
  imported medicines is 370 mil. Euros
 According to number of boxes of medicines sold: domestic producers supply the market with
  around 75% of medicines, reaching around 45% of the cash flow (this difference is caused by the
  difference in price of domestic medicines which is significantly lower than the price of imported
  medicines)
TRADE FLOW OF MEDICINES IN SERBIA IN 2011
                                                        Hemofarm A.D.
                                                        Galenika A.D
                                                        Zdravlje A.D.
                                                        F.Hoffmann-La Roche LTD.
                                                        Glaxosmithkline SPA
                                                        Pfizer H.C.P. Corporation
                    21%                          26%    Sanofi-Aventis S.P.A.
             1%                                         Novo Nordisk A/S
     1% 1%        SERBIAN                               Alkaloid A.D.

      1%                                                Jugoremedija A.D.
                                                        Krka Tovarna Zdravil D.D.

    1% 1%                                               Bristol-Myers Squibb
                                                        Pharmaswiss D.O.O.
      2%                                                Novartis Pharma AG
       2%                                         13%
             2%                             6%          Ferring international center SA

              2%    2% 3% 3%   3%   4%                  Schering AG
                                                        Janssen-Cilag International N.V.
               2% 2%                                    Astra Zeneca UK Limited
                                                        Merck Sharp & Dohme BV
                                                        Habit Pharm A.D.
                                                        Ostalo
TRADE BALANCE

 Export of medicines in 2011 was 208,3 mil. dollars (index for 2011 / 2010 was109)
 The highest export was in Russian Federation (50 mil.), Germany (40 mil.), Montenegro, Bosnia
  and Herzegovina, Bulgaria, Macedonia
 Export in Italy was 2,2 mil. dollars in 2011
 We believe that opportunities are a lot bigger
 Import of medicines was (mostly from EU): it is growing on yearly basis - export in 2011 reached
  525,9 mil USD (index for 2011 / 2010 was 101)
 The highest import was from Germany (99 mil.), France (76 mil.), Italy 47 mil. USD, Great Britain 30
  mil. Denmark, etc.
TRENDS IN IMPORT AND EXPORT OF MEDICINES IN SERBIA (CARTAR 3003, 3004)




                 SERBIAN
SERBIAN
OWNERSHIP STRUCTURE


   Privatized companies                             Non-privatized companies

      Hemofarm - Stada Nemačka                      Galenika Zemun - 2400 employees
      Zdravlje - Actavis Island                     Institute for Immunology and Virology Torlak -
      Pharmaswiss Švajcarska                         400 employees
      Alkaloid Makedonija                           Jugoremedija - 450 employees
                           SERBIAN
      Pharmanova
      Slaviamed
      Ivančić i sinovi



Participation of Italian companies is expected in process of privatization of not privatized companies
(Galenika, Torlak, Jugoremedija)
PRESENCE OF FOREIGN COMPANIES


 The Highest number of multinational companies are present today in Serbian market through
  import and licensed products or through market agreements with domestic companies
 Around 70 foreign pharmaceutical companies have its representative offices in Serbia
 Table 1                                               Table 2
 ТОР10 foreign manufactures in Serbia pharmaceutical   ТОР10 foreign manufactures in Serbia pharmaceutical market ( by
 market ( by share in value terms), Q3SERBIAN
                                      2011             share in real terms), Q3 2011
ITALIAN COMPANIES PRESENT IN SERBIA

 ABBOT S.R.L.                      MERCK SHARP & DOHME S.P.A.
 ACTAVIS ITALY S.P.A.              NOVARTIS FARMA S.P.A.
 BAYER HEALTHCARE                  PFIZER ITALIA S.R.L.
  MANUFACTURING S.R.L.              PHARMATEX ITALIA SRL.
 CATALENT ITALY S.P.A.             ROTTAPHARM S.P.A.
 DOMPE PHARMA S.P.A.  SERBIAN
                                    SIGMAR ITALIA S.P.A.
 ELI LILLY ITALIA S.P.A.           ZAMBON S.P.A.
 FRESENIUS KABI ITALIA S.R.L.
 GLAXOSMITHKLINE SP
 HAUPT PHARMA LATINA
 ISTITUTO DE ANGELI S.R.L
 LABORATORI BALDACCI S.P.A.
 MERCK SERONO S.P.A.
DISTRIBUTION OF MEDICINES

 Distribution of medicines in Serbia is done through wholesalers
 75 % medicines and medical devices are done through 17 wholesales gathered in
  group of wholesalers with around 2500 employees
 All wholesalers meet the requirements specified in the Book of rules on conditions for
  wholesale of medicines and medical devices, and the majority of its members conduct
                         SERBIAN
  their business with implemented ISO quality standards
 Following link in supply chain of medicines in Serbia are pharmacies (state and
  privately owned)
AGENCY FOR MEDICINES AND MEDICAL DEVICES OF SERBIA

   Issues permits for medicines
   Registers medical devices in the Register of Medical Devices
   Conducts a registration of traditional herbal medicines
   Issues permits for clinical testing of medicines and medical devices
   Performs control of clinical testing
   Issues certificates for export of medicines and medical devices
                           SERBIAN
   Approves import of medical devices for patient’s needs
   Approves import of medicines for scientific testing
   Controls the quality of medicines and medical devices
   Participates in development of regulations and national policy in the field of medicines and medical
    devices
PROCEDURE FOR MEDICINES REGISTRATION
Agency for medicines and medical devices

In Serbia, a permit for medicine can be given to:

 A producer that has a permit to produce medicines in the Republic of Serbia
 Representative of foreign producer that has headquarters in the Republic of Serbia
 Representative of foreign legal entity that is not a producer of that medicine but has a permit for
                        SERBIAN
  that medicine in the countries of the EU or in countries that proscribe same requirements for
  permits issuance as that of the Republic of Serbia
 Legal entity with headquarters in the Republic of Serbia that received a permit for the medicine
  from a producer in Serbia, that is that provided him with conditions to become a receiver of the
  medicine permit from their own production program


Medicine permit is being renewed every five years, and after risk and benefits evaluations have
                                         been made
ACCESSIBILITY VS AVAILABILITY

Who is responsible for access and availability of medicines?



               Accessibility                             AVAILABILITY
                Government
                         SERBIAN                           Producers
           Health Insurance Fund                          Wholesalers
   Regulatory bodies (AMMD, Ministry of        Health institutions (pharmaceutical
      Health and Ministry of Trade)            institutions, pharmacies, hospitals)
REGULATIONS

 Law on Medicines and Medical Devices (Official Gazette of RS no. 30, May 7th, 2010)
 Subact
 Regulation on conditions for trade with medicines and medical devices (Official Gazette of RS no. 27
  March 17th , 2008)
 Guidelines for Good practice in Distribution of Medicines (Official Gazette of RS no. 28, March 18th
  2008)
                          SERBIAN
 Regulation on conditions for import of medicines and medical devices which do not have a permit to
  be distributed (Official Gazette if RS no. 37, April 11, 2008)
 Book of rules on amendments and remarks, Book of rules on content and inner and outer labeling of
  medicine packaging and on patient’s /user’s instructions (Official Gazette RS 104, December 16 th
  2009)
 Regulation on Medical Waste Management (Official Gazette of RS no 78, October 25th 2010)
CONCLUSION

Advantages
 Serbia has a status of potential candidate for EU membership
 Economy of the country needs significant investments in domestic pharmaceutical sector
 A lot more stable conditions for FDI and domestic development
 Good economic and political cooperation with Russia provide access to this big market
                       SERBIAN
Opportunities
 Gradual integration in EU and future membership should provide quicker reforms
 Privatization and modernization of domestic pharmaceutical producers provide higher chances for
   export
 Investments and improvements of healthcare program will be promoted by the Government
 Shortened procedures for registration of generics for both foreign and domestic producers
THANK YOU FOR YOUR
    ATTENTION!

     phone: + 381 63 3233 671
       cell: + 381 63 336 743
  e-mail: vekoslav.sosevic@pks.rs
              www.pks.rs

Weitere ähnliche Inhalte

Ähnlich wie Serbia - Farmaceutico, biotecnologie

Pharmaceutical licensing in oncology
Pharmaceutical licensing in oncology Pharmaceutical licensing in oncology
Pharmaceutical licensing in oncology Pipelinepharma
 
Generics and Biogenerics
Generics and BiogenericsGenerics and Biogenerics
Generics and Biogenericsinemet
 
Pharmaceutical Distribution Factbook Austria
Pharmaceutical Distribution Factbook AustriaPharmaceutical Distribution Factbook Austria
Pharmaceutical Distribution Factbook Austriai2k services GmbH
 
Pharmaceutical market of Uzbekistan
Pharmaceutical market of UzbekistanPharmaceutical market of Uzbekistan
Pharmaceutical market of UzbekistanVAYTON
 
Duphat brochure 2020
Duphat brochure 2020Duphat brochure 2020
Duphat brochure 2020AnkitNigam38
 
Duphat brochure 2019
Duphat brochure 2019 Duphat brochure 2019
Duphat brochure 2019 AnkitNigam38
 
American Healthcare and Natural Products Expo 2013
American Healthcare and Natural Products Expo 2013American Healthcare and Natural Products Expo 2013
American Healthcare and Natural Products Expo 2013Via Expo
 
Regulatory authorities of copyright liasion
Regulatory authorities of copyright liasionRegulatory authorities of copyright liasion
Regulatory authorities of copyright liasionRAMZAHASHMI
 
Final Self Medication In Croatia Du 26.5.07
Final Self Medication In Croatia Du 26.5.07Final Self Medication In Croatia Du 26.5.07
Final Self Medication In Croatia Du 26.5.07inemet
 
Hiv Drug Distribution in developing countries.
Hiv Drug Distribution in developing countries.Hiv Drug Distribution in developing countries.
Hiv Drug Distribution in developing countries.hitjl
 
The pharma outlook 2015
The pharma outlook 2015 The pharma outlook 2015
The pharma outlook 2015 Namdeo Shinde
 
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS.
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS. TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS.
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS. Shantanu Kumar Singh
 
FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015
FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015
FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015Sabarinath Suryaprakash
 
Noor Mehar presentation
Noor Mehar presentationNoor Mehar presentation
Noor Mehar presentationKalim Ullah
 
Mm II Assignment
Mm II AssignmentMm II Assignment
Mm II Assignmentamarjit38
 

Ähnlich wie Serbia - Farmaceutico, biotecnologie (20)

Pharmaceutical licensing in oncology
Pharmaceutical licensing in oncology Pharmaceutical licensing in oncology
Pharmaceutical licensing in oncology
 
Generics and Biogenerics
Generics and BiogenericsGenerics and Biogenerics
Generics and Biogenerics
 
Pharmaceutical Distribution Factbook Austria
Pharmaceutical Distribution Factbook AustriaPharmaceutical Distribution Factbook Austria
Pharmaceutical Distribution Factbook Austria
 
Pharmaceutical market of Uzbekistan
Pharmaceutical market of UzbekistanPharmaceutical market of Uzbekistan
Pharmaceutical market of Uzbekistan
 
Duphat brochure 2020
Duphat brochure 2020Duphat brochure 2020
Duphat brochure 2020
 
Duphat brochure 2019
Duphat brochure 2019 Duphat brochure 2019
Duphat brochure 2019
 
American Healthcare and Natural Products Expo 2013
American Healthcare and Natural Products Expo 2013American Healthcare and Natural Products Expo 2013
American Healthcare and Natural Products Expo 2013
 
Regulatory authorities of copyright liasion
Regulatory authorities of copyright liasionRegulatory authorities of copyright liasion
Regulatory authorities of copyright liasion
 
Final Self Medication In Croatia Du 26.5.07
Final Self Medication In Croatia Du 26.5.07Final Self Medication In Croatia Du 26.5.07
Final Self Medication In Croatia Du 26.5.07
 
Novartis
NovartisNovartis
Novartis
 
Hiv Drug Distribution in developing countries.
Hiv Drug Distribution in developing countries.Hiv Drug Distribution in developing countries.
Hiv Drug Distribution in developing countries.
 
Ophaco Belgium
Ophaco BelgiumOphaco Belgium
Ophaco Belgium
 
The pharma outlook 2015
The pharma outlook 2015 The pharma outlook 2015
The pharma outlook 2015
 
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS.
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS. TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS.
TO STUDY THE RECALLED DRUG RANITIDINE HYDROCHLORIDES IN DIFFERENT FORMULATIONS.
 
FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015
FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015
FULL DETAIL OF SUN PHARMA & PHARMACEUTICAL INDUSTRY 2015
 
SUN PHARMA & PHARMA INDUSTRY 2015
SUN PHARMA &  PHARMA INDUSTRY 2015SUN PHARMA &  PHARMA INDUSTRY 2015
SUN PHARMA & PHARMA INDUSTRY 2015
 
Noor Mehar presentation
Noor Mehar presentationNoor Mehar presentation
Noor Mehar presentation
 
Mm II Assignment
Mm II AssignmentMm II Assignment
Mm II Assignment
 
Secof
SecofSecof
Secof
 
Session1: Patrick Deboyser, European Union
Session1: Patrick Deboyser, European UnionSession1: Patrick Deboyser, European Union
Session1: Patrick Deboyser, European Union
 

Mehr von Lazio Innova

Presentazione Bando APEA
Presentazione Bando APEAPresentazione Bando APEA
Presentazione Bando APEALazio Innova
 
Opportunità di internazionalizzazione e innovazione del settore AgriFood del ...
Opportunità di internazionalizzazione e innovazione del settore AgriFood del ...Opportunità di internazionalizzazione e innovazione del settore AgriFood del ...
Opportunità di internazionalizzazione e innovazione del settore AgriFood del ...Lazio Innova
 
Intelligenza artificiale e big data per il monitoraggio delle infrastrutture ...
Intelligenza artificiale e big data per il monitoraggio delle infrastrutture ...Intelligenza artificiale e big data per il monitoraggio delle infrastrutture ...
Intelligenza artificiale e big data per il monitoraggio delle infrastrutture ...Lazio Innova
 
Jetware premiazione pitch
Jetware premiazione pitchJetware premiazione pitch
Jetware premiazione pitchLazio Innova
 
Rendicontazione delle spese
Rendicontazione delle spese Rendicontazione delle spese
Rendicontazione delle spese Lazio Innova
 
Verso il bando Infrastrutture per la ricerca
Verso il bando Infrastrutture per la ricercaVerso il bando Infrastrutture per la ricerca
Verso il bando Infrastrutture per la ricercaLazio Innova
 
Presentazione del bando "Sostegno alle APEA"
Presentazione del bando "Sostegno alle APEA"Presentazione del bando "Sostegno alle APEA"
Presentazione del bando "Sostegno alle APEA"Lazio Innova
 
Presentazione Progetto Rinasce
Presentazione Progetto RinascePresentazione Progetto Rinasce
Presentazione Progetto RinasceLazio Innova
 
La sfida della sostenibilità ambientale: il ruolo della politica
La sfida della sostenibilità ambientale: il ruolo della politicaLa sfida della sostenibilità ambientale: il ruolo della politica
La sfida della sostenibilità ambientale: il ruolo della politicaLazio Innova
 
RIUSA - Presentazione Prof. Massimiliano Barletta
RIUSA - Presentazione Prof. Massimiliano BarlettaRIUSA - Presentazione Prof. Massimiliano Barletta
RIUSA - Presentazione Prof. Massimiliano BarlettaLazio Innova
 
FONDO FUTURO 2014-2020
FONDO FUTURO 2014-2020FONDO FUTURO 2014-2020
FONDO FUTURO 2014-2020Lazio Innova
 
Presentazione Bando DTC
Presentazione Bando DTCPresentazione Bando DTC
Presentazione Bando DTCLazio Innova
 
Bandi artigianato e internazionalizzazione
Bandi artigianato e internazionalizzazioneBandi artigianato e internazionalizzazione
Bandi artigianato e internazionalizzazioneLazio Innova
 
LAZIO GREEN – IL FUTURO SOSTENIBILE
LAZIO GREEN – IL FUTURO SOSTENIBILELAZIO GREEN – IL FUTURO SOSTENIBILE
LAZIO GREEN – IL FUTURO SOSTENIBILELazio Innova
 
Il Fondo Rotativo per il Piccolo Credito
Il Fondo Rotativo per il Piccolo CreditoIl Fondo Rotativo per il Piccolo Credito
Il Fondo Rotativo per il Piccolo CreditoLazio Innova
 
Il POR FESR Lazio 2014-2020 OT, Priorità e Azioni
Il POR FESR Lazio 2014-2020 OT,  Priorità e AzioniIl POR FESR Lazio 2014-2020 OT,  Priorità e Azioni
Il POR FESR Lazio 2014-2020 OT, Priorità e AzioniLazio Innova
 

Mehr von Lazio Innova (20)

Presentazione Bando APEA
Presentazione Bando APEAPresentazione Bando APEA
Presentazione Bando APEA
 
Opportunità di internazionalizzazione e innovazione del settore AgriFood del ...
Opportunità di internazionalizzazione e innovazione del settore AgriFood del ...Opportunità di internazionalizzazione e innovazione del settore AgriFood del ...
Opportunità di internazionalizzazione e innovazione del settore AgriFood del ...
 
Urbyet orbit
Urbyet orbitUrbyet orbit
Urbyet orbit
 
Intelligenza artificiale e big data per il monitoraggio delle infrastrutture ...
Intelligenza artificiale e big data per il monitoraggio delle infrastrutture ...Intelligenza artificiale e big data per il monitoraggio delle infrastrutture ...
Intelligenza artificiale e big data per il monitoraggio delle infrastrutture ...
 
Neural research
Neural researchNeural research
Neural research
 
Latitudo 40 earth
Latitudo 40 earthLatitudo 40 earth
Latitudo 40 earth
 
Kuaternion pitch
Kuaternion pitchKuaternion pitch
Kuaternion pitch
 
Jetware premiazione pitch
Jetware premiazione pitchJetware premiazione pitch
Jetware premiazione pitch
 
Rendicontazione delle spese
Rendicontazione delle spese Rendicontazione delle spese
Rendicontazione delle spese
 
Verso il bando Infrastrutture per la ricerca
Verso il bando Infrastrutture per la ricercaVerso il bando Infrastrutture per la ricerca
Verso il bando Infrastrutture per la ricerca
 
Presentazione del bando "Sostegno alle APEA"
Presentazione del bando "Sostegno alle APEA"Presentazione del bando "Sostegno alle APEA"
Presentazione del bando "Sostegno alle APEA"
 
Presentazione Progetto Rinasce
Presentazione Progetto RinascePresentazione Progetto Rinasce
Presentazione Progetto Rinasce
 
La sfida della sostenibilità ambientale: il ruolo della politica
La sfida della sostenibilità ambientale: il ruolo della politicaLa sfida della sostenibilità ambientale: il ruolo della politica
La sfida della sostenibilità ambientale: il ruolo della politica
 
RIUSA - Presentazione Prof. Massimiliano Barletta
RIUSA - Presentazione Prof. Massimiliano BarlettaRIUSA - Presentazione Prof. Massimiliano Barletta
RIUSA - Presentazione Prof. Massimiliano Barletta
 
FONDO FUTURO 2014-2020
FONDO FUTURO 2014-2020FONDO FUTURO 2014-2020
FONDO FUTURO 2014-2020
 
Presentazione Bando DTC
Presentazione Bando DTCPresentazione Bando DTC
Presentazione Bando DTC
 
Bandi artigianato e internazionalizzazione
Bandi artigianato e internazionalizzazioneBandi artigianato e internazionalizzazione
Bandi artigianato e internazionalizzazione
 
LAZIO GREEN – IL FUTURO SOSTENIBILE
LAZIO GREEN – IL FUTURO SOSTENIBILELAZIO GREEN – IL FUTURO SOSTENIBILE
LAZIO GREEN – IL FUTURO SOSTENIBILE
 
Il Fondo Rotativo per il Piccolo Credito
Il Fondo Rotativo per il Piccolo CreditoIl Fondo Rotativo per il Piccolo Credito
Il Fondo Rotativo per il Piccolo Credito
 
Il POR FESR Lazio 2014-2020 OT, Priorità e Azioni
Il POR FESR Lazio 2014-2020 OT,  Priorità e AzioniIl POR FESR Lazio 2014-2020 OT,  Priorità e Azioni
Il POR FESR Lazio 2014-2020 OT, Priorità e Azioni
 

Serbia - Farmaceutico, biotecnologie

  • 1. PHARMACEUTICAL SECTOR OF SERBIA Vekoslav Šošević, Secretary of Association of Chemical and Pharmaceutical Industry, Rubber and Non-Metal Industry 25 th October 2012, Rome
  • 2. PHARMACEUTICAL INDUSTRY - ECONOMIC OVERVIEW  Share of pharmaceutical sector in GDP - 0,7%  Gross production of the industry - over 450 mil. Euro (2011)  Total consumption of medicines in Serbia - 740 mil. Euro  Annual production rate ~10%  Number of employees - 7000  Export oriented (155 mil Euro of goods were exported in 2011)  Direct contribution to the budget of the Republic of Serbia (2011) ~40 mil. Euro (taxes, contribution, customs)
  • 3. TRADE FLOW OF DOMESTIC PRODUCERS FROM SERBIA IN 2011  For years, domestic pharmaceutical industry has been a carrier of stable supply of the market with medicines of all forms and dosages  Total consumption of medicines in Serbia for 2011 is estimated to around 740 mil. Euros. Share of imported medicines is 370 mil. Euros  According to number of boxes of medicines sold: domestic producers supply the market with around 75% of medicines, reaching around 45% of the cash flow (this difference is caused by the difference in price of domestic medicines which is significantly lower than the price of imported medicines)
  • 4. TRADE FLOW OF MEDICINES IN SERBIA IN 2011 Hemofarm A.D. Galenika A.D Zdravlje A.D. F.Hoffmann-La Roche LTD. Glaxosmithkline SPA Pfizer H.C.P. Corporation 21% 26% Sanofi-Aventis S.P.A. 1% Novo Nordisk A/S 1% 1% SERBIAN Alkaloid A.D. 1% Jugoremedija A.D. Krka Tovarna Zdravil D.D. 1% 1% Bristol-Myers Squibb Pharmaswiss D.O.O. 2% Novartis Pharma AG 2% 13% 2% 6% Ferring international center SA 2% 2% 3% 3% 3% 4% Schering AG Janssen-Cilag International N.V. 2% 2% Astra Zeneca UK Limited Merck Sharp & Dohme BV Habit Pharm A.D. Ostalo
  • 5. TRADE BALANCE  Export of medicines in 2011 was 208,3 mil. dollars (index for 2011 / 2010 was109)  The highest export was in Russian Federation (50 mil.), Germany (40 mil.), Montenegro, Bosnia and Herzegovina, Bulgaria, Macedonia  Export in Italy was 2,2 mil. dollars in 2011  We believe that opportunities are a lot bigger  Import of medicines was (mostly from EU): it is growing on yearly basis - export in 2011 reached 525,9 mil USD (index for 2011 / 2010 was 101)  The highest import was from Germany (99 mil.), France (76 mil.), Italy 47 mil. USD, Great Britain 30 mil. Denmark, etc.
  • 6. TRENDS IN IMPORT AND EXPORT OF MEDICINES IN SERBIA (CARTAR 3003, 3004) SERBIAN
  • 8. OWNERSHIP STRUCTURE Privatized companies Non-privatized companies  Hemofarm - Stada Nemačka  Galenika Zemun - 2400 employees  Zdravlje - Actavis Island  Institute for Immunology and Virology Torlak -  Pharmaswiss Švajcarska 400 employees  Alkaloid Makedonija  Jugoremedija - 450 employees SERBIAN  Pharmanova  Slaviamed  Ivančić i sinovi Participation of Italian companies is expected in process of privatization of not privatized companies (Galenika, Torlak, Jugoremedija)
  • 9. PRESENCE OF FOREIGN COMPANIES  The Highest number of multinational companies are present today in Serbian market through import and licensed products or through market agreements with domestic companies  Around 70 foreign pharmaceutical companies have its representative offices in Serbia Table 1 Table 2 ТОР10 foreign manufactures in Serbia pharmaceutical ТОР10 foreign manufactures in Serbia pharmaceutical market ( by market ( by share in value terms), Q3SERBIAN 2011 share in real terms), Q3 2011
  • 10. ITALIAN COMPANIES PRESENT IN SERBIA  ABBOT S.R.L.  MERCK SHARP & DOHME S.P.A.  ACTAVIS ITALY S.P.A.  NOVARTIS FARMA S.P.A.  BAYER HEALTHCARE  PFIZER ITALIA S.R.L. MANUFACTURING S.R.L.  PHARMATEX ITALIA SRL.  CATALENT ITALY S.P.A.  ROTTAPHARM S.P.A.  DOMPE PHARMA S.P.A. SERBIAN  SIGMAR ITALIA S.P.A.  ELI LILLY ITALIA S.P.A.  ZAMBON S.P.A.  FRESENIUS KABI ITALIA S.R.L.  GLAXOSMITHKLINE SP  HAUPT PHARMA LATINA  ISTITUTO DE ANGELI S.R.L  LABORATORI BALDACCI S.P.A.  MERCK SERONO S.P.A.
  • 11. DISTRIBUTION OF MEDICINES  Distribution of medicines in Serbia is done through wholesalers  75 % medicines and medical devices are done through 17 wholesales gathered in group of wholesalers with around 2500 employees  All wholesalers meet the requirements specified in the Book of rules on conditions for wholesale of medicines and medical devices, and the majority of its members conduct SERBIAN their business with implemented ISO quality standards  Following link in supply chain of medicines in Serbia are pharmacies (state and privately owned)
  • 12. AGENCY FOR MEDICINES AND MEDICAL DEVICES OF SERBIA  Issues permits for medicines  Registers medical devices in the Register of Medical Devices  Conducts a registration of traditional herbal medicines  Issues permits for clinical testing of medicines and medical devices  Performs control of clinical testing  Issues certificates for export of medicines and medical devices SERBIAN  Approves import of medical devices for patient’s needs  Approves import of medicines for scientific testing  Controls the quality of medicines and medical devices  Participates in development of regulations and national policy in the field of medicines and medical devices
  • 13. PROCEDURE FOR MEDICINES REGISTRATION Agency for medicines and medical devices In Serbia, a permit for medicine can be given to:  A producer that has a permit to produce medicines in the Republic of Serbia  Representative of foreign producer that has headquarters in the Republic of Serbia  Representative of foreign legal entity that is not a producer of that medicine but has a permit for SERBIAN that medicine in the countries of the EU or in countries that proscribe same requirements for permits issuance as that of the Republic of Serbia  Legal entity with headquarters in the Republic of Serbia that received a permit for the medicine from a producer in Serbia, that is that provided him with conditions to become a receiver of the medicine permit from their own production program Medicine permit is being renewed every five years, and after risk and benefits evaluations have been made
  • 14. ACCESSIBILITY VS AVAILABILITY Who is responsible for access and availability of medicines? Accessibility AVAILABILITY Government SERBIAN Producers Health Insurance Fund Wholesalers Regulatory bodies (AMMD, Ministry of Health institutions (pharmaceutical Health and Ministry of Trade) institutions, pharmacies, hospitals)
  • 15. REGULATIONS  Law on Medicines and Medical Devices (Official Gazette of RS no. 30, May 7th, 2010)  Subact  Regulation on conditions for trade with medicines and medical devices (Official Gazette of RS no. 27 March 17th , 2008)  Guidelines for Good practice in Distribution of Medicines (Official Gazette of RS no. 28, March 18th 2008) SERBIAN  Regulation on conditions for import of medicines and medical devices which do not have a permit to be distributed (Official Gazette if RS no. 37, April 11, 2008)  Book of rules on amendments and remarks, Book of rules on content and inner and outer labeling of medicine packaging and on patient’s /user’s instructions (Official Gazette RS 104, December 16 th 2009)  Regulation on Medical Waste Management (Official Gazette of RS no 78, October 25th 2010)
  • 16. CONCLUSION Advantages  Serbia has a status of potential candidate for EU membership  Economy of the country needs significant investments in domestic pharmaceutical sector  A lot more stable conditions for FDI and domestic development  Good economic and political cooperation with Russia provide access to this big market SERBIAN Opportunities  Gradual integration in EU and future membership should provide quicker reforms  Privatization and modernization of domestic pharmaceutical producers provide higher chances for export  Investments and improvements of healthcare program will be promoted by the Government  Shortened procedures for registration of generics for both foreign and domestic producers
  • 17. THANK YOU FOR YOUR ATTENTION! phone: + 381 63 3233 671 cell: + 381 63 336 743 e-mail: vekoslav.sosevic@pks.rs www.pks.rs